CA2148829A1 - Vaccin vivant avirulent et methode pour immuniser les animaux contre p. multocida pasteurellosis - Google Patents
Vaccin vivant avirulent et methode pour immuniser les animaux contre p. multocida pasteurellosisInfo
- Publication number
- CA2148829A1 CA2148829A1 CA002148829A CA2148829A CA2148829A1 CA 2148829 A1 CA2148829 A1 CA 2148829A1 CA 002148829 A CA002148829 A CA 002148829A CA 2148829 A CA2148829 A CA 2148829A CA 2148829 A1 CA2148829 A1 CA 2148829A1
- Authority
- CA
- Canada
- Prior art keywords
- mutant
- multocida
- transposon
- avirulent
- pasteurellosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000606856 Pasteurella multocida Species 0.000 title claims abstract description 94
- 241001465754 Metazoa Species 0.000 title claims abstract description 60
- 206010034107 Pasteurella infections Diseases 0.000 title claims abstract description 56
- 201000005115 pasteurellosis Diseases 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 35
- 229960005486 vaccine Drugs 0.000 title claims abstract description 32
- 230000003053 immunization Effects 0.000 title claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 104
- 230000001404 mediated effect Effects 0.000 claims abstract description 41
- 230000002163 immunogen Effects 0.000 claims abstract description 34
- 239000000304 virulence factor Substances 0.000 claims abstract description 25
- 230000007923 virulence factor Effects 0.000 claims abstract description 24
- 238000003780 insertion Methods 0.000 claims description 46
- 230000037431 insertion Effects 0.000 claims description 45
- 239000012634 fragment Substances 0.000 claims description 33
- 230000036039 immunity Effects 0.000 claims description 25
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 20
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 16
- 239000013612 plasmid Substances 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000001018 virulence Effects 0.000 abstract description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 201000010099 disease Diseases 0.000 description 20
- 238000002703 mutagenesis Methods 0.000 description 17
- 231100000350 mutagenesis Toxicity 0.000 description 17
- 238000010561 standard procedure Methods 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 241000286209 Phasianidae Species 0.000 description 14
- 230000000680 avirulence Effects 0.000 description 14
- 230000000295 complement effect Effects 0.000 description 13
- 239000003550 marker Substances 0.000 description 13
- 230000005923 long-lasting effect Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 206010008631 Cholera Diseases 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 241000271566 Aves Species 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000272517 Anseriformes Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000012239 gene modification Methods 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 4
- 235000013617 genetically modified food Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 229940051027 pasteurella multocida Drugs 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000007923 nasal drop Substances 0.000 description 3
- 229940100662 nasal drops Drugs 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000017105 transposition Effects 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108010028773 Complement C5 Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- 101001056675 Klebsiella pneumoniae Ferric aerobactin receptor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000288147 Meleagris gallopavo Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000014122 turkey meat Nutrition 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97307092A | 1992-11-06 | 1992-11-06 | |
| US07/973,070 | 1992-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2148829A1 true CA2148829A1 (fr) | 1994-05-26 |
Family
ID=25520459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002148829A Abandoned CA2148829A1 (fr) | 1992-11-06 | 1993-11-05 | Vaccin vivant avirulent et methode pour immuniser les animaux contre p. multocida pasteurellosis |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0668779A4 (fr) |
| JP (1) | JPH08503136A (fr) |
| AU (1) | AU5591694A (fr) |
| CA (1) | CA2148829A1 (fr) |
| WO (1) | WO1994011024A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2623339C (fr) | 1994-12-09 | 2012-05-08 | David William Holden | Genes de virulence dans la region vgc2 de salmonella |
| ES2356863T3 (es) | 1998-09-04 | 2011-04-13 | Emergent Product Development Uk Limited | Mutantes de spi2 de salmonella atenuada como portadores de antígenos. |
| US6790950B2 (en) | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
| AU2010201539C1 (en) * | 1999-04-09 | 2016-06-16 | Zoetis Services Llc | Anti-bacterial vaccine compositions |
| AU780887B2 (en) * | 1999-04-09 | 2005-04-21 | Zoetis Services Llc | Anti-bacterial vaccine compositions |
| AU2013201267B2 (en) * | 1999-04-09 | 2016-03-17 | Zoetis Services Llc | Anti-bacterial vaccine compositions |
| GB9910812D0 (en) | 1999-05-10 | 1999-07-07 | Microscience Ltd | Vaccine composition |
| US7449178B2 (en) | 2002-04-05 | 2008-11-11 | Merial Limited | Attenuated gram negative bacteria |
| ES2346915T3 (es) * | 2002-04-05 | 2010-10-21 | Merial | Bacterias gram negativas atenuadas. |
| CN101496899B (zh) * | 2004-08-20 | 2011-08-24 | 简茂盛 | 猪进行性萎缩性鼻炎的预防、治疗与检测 |
| MX2007007570A (es) * | 2004-12-22 | 2007-07-24 | Intervet Int Bv | Vacuna de pasteurella multocida. |
| CL2008000856A1 (es) * | 2007-03-26 | 2008-05-30 | Wyeth Corp | Uso de una pasteurella multocida mutante acapsular y atenuada para inducir inmunidad protectora cruzada en un animal contra p. multocida virulenta que tiene un serotipo diferente al de p. multocida mutante. |
| ES2824402T3 (es) | 2013-11-01 | 2021-05-12 | Boehringer Ingelheim Animal Health Usa Inc | Vacunas atenuadas contra Pasteurella multocida y procedimientos de fabricación y uso de las mismas |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3855408A (en) * | 1973-07-16 | 1974-12-17 | Univ Minnesota | Poultry vaccine |
| IL52815A (en) * | 1977-08-24 | 1983-03-31 | Israel State | Fowl cholera vaccine and process for producing an attenuated non-virulent strain of pasteurella multocida |
| US4337314A (en) * | 1979-05-23 | 1982-06-29 | Research Corporation | Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype |
| US4293545A (en) * | 1980-03-31 | 1981-10-06 | Norden Laboratories, Inc. | Modified Pasteurella multocida bacteria vaccines |
| US4735801A (en) * | 1982-09-07 | 1988-04-05 | Board Of Trustees Of Leland Stanford Jr. University | Novel non-reverting salmonella live vaccines |
| DE3882781T3 (de) * | 1987-03-24 | 2000-04-06 | British Technology Group Ltd. | Impfstoff gegen Pasteurella. |
| DK199588D0 (da) * | 1988-04-12 | 1988-04-12 | Nordisk Droge & Kemikalie | Vaccine |
| US4999191A (en) * | 1988-05-05 | 1991-03-12 | University Of Georgia Research Foundation, Inc. | Pasteurella multocida vaccine |
-
1993
- 1993-11-05 WO PCT/US1993/010600 patent/WO1994011024A1/fr not_active Application Discontinuation
- 1993-11-05 CA CA002148829A patent/CA2148829A1/fr not_active Abandoned
- 1993-11-05 EP EP94901259A patent/EP0668779A4/fr not_active Withdrawn
- 1993-11-05 JP JP6512199A patent/JPH08503136A/ja active Pending
- 1993-11-05 AU AU55916/94A patent/AU5591694A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0668779A1 (fr) | 1995-08-30 |
| WO1994011024A1 (fr) | 1994-05-26 |
| JPH08503136A (ja) | 1996-04-09 |
| AU5591694A (en) | 1994-06-08 |
| EP0668779A4 (fr) | 1996-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU623599B2 (en) | Avirulent microbes, incapable of producing functional adenylate cyclase and cyclic amp | |
| FI121601B (fi) | Virulenssigeeni | |
| US5387744A (en) | Avirulent microbes and uses therefor: Salmonella typhi | |
| US5294441A (en) | Avirulent microbes and uses therefor: salmonella typhi | |
| KR100202771B1 (ko) | 미생물감염에대한숙주의예방적치료용백신 | |
| EP0876150B1 (fr) | Mutants non toxiques de bacteries pathogenes gram-negatives | |
| US5855880A (en) | Avirulent microbes and uses therefor | |
| CA2148829A1 (fr) | Vaccin vivant avirulent et methode pour immuniser les animaux contre p. multocida pasteurellosis | |
| WO1997019688A9 (fr) | Mutants non toxiques de bacteries pathogenes gram-negatives | |
| Guidolin et al. | Genetics of Vibrio cholerae and its bacteriophages | |
| KR101176717B1 (ko) | 약독화된 마이코플라즈마 갈리셉티쿰 균주 | |
| CA2241626A1 (fr) | Mutants de riboflavine utilises en tant que vaccins contre actinobacillus pleuropneumoniae | |
| EP2281834B1 (fr) | Bactéries atténuées de la Famille Pasteurellaceae comprenant un gène muté de virulence | |
| US5840312A (en) | Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein | |
| Iteman et al. | Relationship between loss of pigmentation and deletion of the chromosomal iron-regulated irp2 gene in Yersinia pestis: evidence for separate but related events | |
| US8071356B2 (en) | Salmonella enterica strains of reduced pathogenicity, method for their preparation and uses thereof | |
| AU666108B2 (en) | CDT mutants of salmonella typhi | |
| CN100435845C (zh) | 抗猪胸膜肺炎的减毒活疫苗 | |
| CA2013572A1 (fr) | Microbes non virulents et leur utilisation | |
| IE84199B1 (en) | Avirulent salmonella microbes comprising a mutation in the CDT gene and uses therefor | |
| US7597896B2 (en) | Composition comprising a protein encoded by a modified ERP gene of Mycobacterium | |
| SK177198A3 (en) | Recombinant vaccine for diseases caused by encapsulated organisms | |
| HUT52701A (en) | Process for producing vaccine of bordetella pertussis | |
| AU739191B2 (en) | Vaccines containing attenuated bacteria | |
| JPH1075774A (ja) | パスツレラ科の弱毒化ｒｔｘ産生細菌 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |